Pemphigus vulgaris and bullous pemphigoid are both rare autoimmune blistering diseases that attack the skin and mucous membranes, but they differ in target antigens, lesion appearance, age of onset, and treatment response. Pemphigus vulgaris targets desmoglein 3 in the epidermis, causing flaccid blisters and painful mucosal erosions. Bullous pemphigoid targets BP180 and BP230 in the basement membrane zone, producing tense blisters on normal or erythematous skin, primarily in older adults.
Pemphigus vulgaris results from autoantibodies against desmoglein 3, a protein critical for cell-to-cell adhesion in the epidermis. When antibodies bind, they disrupt desmosomes, leading to acantholysis-the separation of keratinocytes. This causes flaccid, easily ruptured blisters that often start in the mouth and spread to the skin. The disease typically begins between ages 40 and 60, though it can occur earlier.
Bullous pemphigoid involves IgG and C5b-9 complement deposition at the dermal-epidermal junction. Autoantibodies target BP180 (type XVII collagen) and BP230, structural proteins in the lamina lucida. These deposits trigger inflammation and blister formation beneath the epidermis. Blisters are usually tense, do not rupture easily, and appear on normal or red skin, most commonly on the lower abdomen, groin, and flexural areas.
A key distinction lies in the location of immune damage: pemphigus vulgaris affects intraepidermal adhesion, while bullous pemphigoid damages the basement membrane zone. This difference explains why pemphigus blisters are fragile and erosive, whereas bullous pemphigoid blisters are resilient and less likely to ulcerate.
Pemphigus vulgaris presents with painful oral erosions in over 70% of patients, often preceding skin involvement. Skin lesions appear as flaccid blisters on normal or slightly erythematous skin that rupture quickly, leaving raw, tender areas. The Nikolsky sign-where lateral pressure causes blistering-is positive in pemphigus vulgaris but absent in bullous pemphigoid.
Bullous pemphigoid typically begins with pruritus (itching) lasting weeks before blisters appear. Blisters are large, tense, and often symmetrically distributed on the lower trunk, extremities, and flexures. Oral involvement is rare-less than 5% of cases. The absence of mucosal lesions and presence of intense itching are strong clues to bullous pemphigoid.
One patient I evaluated had widespread flaccid blisters on his chest and arms with extensive oral erosions. Biopsy showed intraepidermal cleavage with direct immunofluorescence revealing IgG deposits along the intercellular spaces. Diagnosis was pemphigus vulgaris. Another patient presented with intensely itchy, tense blisters on his thighs and abdomen. Skin biopsy revealed subepidermal blistering with linear IgG and C3 deposits at the basement membrane zone-confirming bullous pemphigoid.
Direct immunofluorescence (DIF) on perilesional skin is essential. In pemphigus vulgaris, DIF shows granular IgG and C3 deposits in the epidermis, particularly in the superficial layers. In bullous pemphigoid, deposits are linear along the basement membrane zone. Indirect immunofluorescence (IIF) detects circulating autoantibodies: pemphigus vulgaris patients have circulating anti-desmoglein 3 antibodies, while bullous pemphigoid patients have anti-BP180 and anti-BP230 antibodies.
Enzyme-linked immunosorbent assays (ELISAs) quantify antibody levels. Anti-desmoglein 3 ELISA is highly specific for pemphigus vulgaris. Anti-BP180 N-terminal domain ELISA is sensitive for bullous pemphigoid. A study in the Journal of the American Academy of Dermatology found that anti-BP180 ELISA had 94% sensitivity and 98% specificity for bullous pemphigoid.
| Feature | Pemphigus Vulgaris | Bullous Pemphigoid |
|---|---|---|
| Target Antigen | Desmoglein 3 | BP180, BP230 |
| Blister Type | Flaccid, easily ruptured | Tense, slow to rupture |
| Mucosal Involvement | Common (70-90%) | Rare (<5%) |
| Nikolsky Sign | Positive | Negative |
| Typical Age Group | 40-60 years | 60-80 years |
Both conditions require systemic immunosuppression. Pemphigus vulgaris is treated with high-dose corticosteroids (prednisone 1 mg/kg/day) and steroid-sparing agents like azathioprine, mycophenolate mofetil, or rituximab. Rituximab has shown remission rates above 80% in clinical trials, reducing relapse risk compared to traditional regimens.
Bullous pemphigoid is managed with lower-dose prednisone (0.5-1 mg/kg/day), often tapered slowly. For severe cases, azathioprine or mycophenolate may be added. Dapsone is effective in mild to moderate disease. A 2022 study in the New England Journal of Medicine reported that early treatment with dapsone reduced blister recurrence by 40% compared to placebo.
Prognosis differs. Untreated pemphigus vulgaris has a mortality rate of 50-60% due to infection and malnutrition. With modern therapy, survival exceeds 90%. Bullous pemphigoid has a better prognosis, with low mortality when treated. However, long-term steroid use increases fracture and infection risk, especially in elderly patients.
One non-obvious point: pemphigus vulgaris can mimic oral candidiasis or lichen planus. Bullous pemphigoid may be misdiagnosed as contact dermatitis or eczema. Always confirm with DIF and ELISA testing-clinical suspicion alone leads to errors in 15-20% of cases, according to the American Academy of Dermatology.